These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 16924447

  • 1. [Age-related macular degeneration: a socioeconomic time bomb in our aging society].
    Schrader WF.
    Ophthalmologe; 2006 Sep; 103(9):742-8. PubMed ID: 16924447
    [Abstract] [Full Text] [Related]

  • 2. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.
    Pharmacoeconomics; 2008 Sep; 26(1):57-73. PubMed ID: 18088159
    [Abstract] [Full Text] [Related]

  • 3. [Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].
    Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HP, Roider I, Mohr A, Zlateva G, Xu X.
    Ophthalmologe; 2009 Mar; 106(3):242-51. PubMed ID: 18709375
    [Abstract] [Full Text] [Related]

  • 4. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I.
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [Abstract] [Full Text] [Related]

  • 5. Treatment Patterns and Health Care Costs for Age-Related Macular Degeneration in Japan: An Analysis of National Insurance Claims Data.
    Kume A, Ohshiro T, Sakurada Y, Kikushima W, Yoneyama S, Kashiwagi K.
    Ophthalmology; 2016 Jun; 123(6):1263-8. PubMed ID: 26927204
    [Abstract] [Full Text] [Related]

  • 6. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
    Coleman AL, Yu F.
    Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
    [Abstract] [Full Text] [Related]

  • 7. Burden of illness of neovascular age-related macular degeneration in Canada.
    Cruess A, Zlateva G, Xu X, Rochon S.
    Can J Ophthalmol; 2007 Dec; 42(6):836-43. PubMed ID: 18026200
    [Abstract] [Full Text] [Related]

  • 8. An epidemiological study of neovascular age-related macular degeneration in Germany.
    Krause L, Yousif T, Pohl K, CAPTAIN study group.
    Curr Med Res Opin; 2013 Oct; 29(10):1391-7. PubMed ID: 23944372
    [Abstract] [Full Text] [Related]

  • 9. Age-related macular degeneration: economic burden and value-based medicine analysis.
    Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR.
    Can J Ophthalmol; 2005 Jun; 40(3):277-87. PubMed ID: 15947797
    [Abstract] [Full Text] [Related]

  • 10. [Cost of illness of age-related macular degeneration. Systematic review on the development of a costs diary].
    Gibbert J, Müller D, Fauser S, Stock S.
    Ophthalmologe; 2013 Jun; 110(6):528-36. PubMed ID: 23297119
    [Abstract] [Full Text] [Related]

  • 11. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.
    Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH, MICMAC (MICro-economics of MACular degeneration) Study Group.
    Drugs Aging; 2008 Jun; 25(3):255-68. PubMed ID: 18331076
    [Abstract] [Full Text] [Related]

  • 12. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
    Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU.
    Hum Gene Ther; 2001 Nov 01; 12(16):2029-32. PubMed ID: 11727737
    [Abstract] [Full Text] [Related]

  • 13. Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy?
    Trevithick J, Massel D, Robertson JM, Tomany S, Wall R.
    Ophthalmic Epidemiol; 2004 Dec 01; 11(5):337-46. PubMed ID: 15590581
    [Abstract] [Full Text] [Related]

  • 14. [Economic Short-Term Cost Model for Stereotactic Radiotherapy of Neovascular AMD].
    Neubauer AS, Reznicek L, Minartz C, Ziemssen F.
    Klin Monbl Augenheilkd; 2016 Aug 01; 233(8):951-7. PubMed ID: 27130973
    [Abstract] [Full Text] [Related]

  • 15. The burden of age-related macular degeneration.
    Schmier JK, Jones ML, Halpern MT.
    Pharmacoeconomics; 2006 Aug 01; 24(4):319-34. PubMed ID: 16605279
    [Abstract] [Full Text] [Related]

  • 16. [Epidemiology of age-related macular degeneration].
    Brandl C, Stark KJ, Wintergerst M, Heinemann M, Heid IM, Finger RP.
    Ophthalmologe; 2016 Sep 01; 113(9):735-45. PubMed ID: 27541733
    [Abstract] [Full Text] [Related]

  • 17. Treatment Options for Age-Related Macular Degeneration: A Budget Impact Analysis from the Perspective of the Brazilian Public Health System.
    Elias FT, Silva EN, Belfort R, Silva MT, Atallah ÁN.
    PLoS One; 2015 Sep 01; 10(10):e0139556. PubMed ID: 26457416
    [Abstract] [Full Text] [Related]

  • 18. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community.
    Evans JR, Fletcher AE, Wormald RP.
    Ophthalmology; 2004 Mar 01; 111(3):513-7. PubMed ID: 15019328
    [Abstract] [Full Text] [Related]

  • 19. The cost-effectiveness of treatment of age-related macular degeneration: a review.
    Kymes Steven M.
    Minerva Med; 2009 Feb 01; 100(1):69-78. PubMed ID: 19277005
    [Abstract] [Full Text] [Related]

  • 20. Age-Related Macular Degeneration.
    Mehta S.
    Prim Care; 2015 Sep 01; 42(3):377-91. PubMed ID: 26319344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.